Established Medical Therapy for Benign Prostatic Hyperplasia

Gregory B. Auffenberg, Brian T. Helfand, Kevin T. McVary*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

85 Scopus citations


Benign prostatic hyperplasia is characterized by smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can cause a variety of problems for a patient, the most frequent being bothersome lower urinary tract symptoms. In most cases, medical therapy has become the first-line treatment modality of choice, with a variety of pharmacologic mechanisms proving to be beneficial. Several large trials have shown the efficacy of alpha-receptor blocking and 5-alpha reductase inhibiting medications when used alone and in combination. Newer data has shown the benefit of anti-muscarinic medications in specific populations who suffer from bladder outlet obstruction causing storage urinary symptoms. Phytotherapeutic supplements are numerous and used frequently; however, data supporting safety and efficacy is limited, making treatment recommendations difficult. The available clinical trial data for all of these types of therapy is discussed in this article.

Original languageEnglish (US)
Pages (from-to)443-459
Number of pages17
JournalUrologic Clinics of North America
Issue number4
StatePublished - Nov 2009


  • 5-alpha reductase inhibitor
  • Alpha-blocker
  • Anti-cholinergic
  • Benign prostatic hyperplasia
  • Phytotherapeutics

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Established Medical Therapy for Benign Prostatic Hyperplasia'. Together they form a unique fingerprint.

Cite this